Bio-Rad Laboratories, Inc has launched a range of anti-vedolizumab antibodies to be used to support research into the treatment of ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Vedolizumab (Entyvio) is a monoclonal antibody used to treat these diseases and Bio-Rad’s anti-vedolizumab antibodies include four recombinant monoclonal anti-idiotypics that are highly specific for this humanised IgG1 kappa drug, making them highly suitable for the development of bioanalytical and patient monitoring assays.
The anti-vedolizumab antibodies are generated using Bio-Rad’s Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display, resulting in highly targeted reagents. These paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. In addition, their recombinant production method ensures a consistent and secure supply.
The new antibodies are approved for in-vitro research purposes and for commercial applications for the provision of in-vitro testing services to support preclinical and clinical drug development and patient monitoring.
For further information about Bio-Rad visit www.bio-rad.com
Latest from Tom Mulligan
- Concept Life Sciences forms Scientific Advisory Board
- Sangamo finalises TxCell acquisition
- Polyplus-transfection introduces new nanoparticle DNA transfection reagent
- The 6th SGS Biopharma Day Seminar: a new early-phase clinical trials paradigm
- Blacktrace expands its presence in Japan with new office in Kanagawa
- MaSTherCell doubles production capacity
- Absolute Antibody expands production facilities
- Optibrium and University of Nottingham collaborate on innovative teaching programme
- Diamond Pharma Services wins both Futures and Support categories at TOPRA Awards
- Droplet microfluidics offers new approach for studying plant cell biomechanics